scholarly journals Ameliorative Effects of Different Transcranial Electrical Stimulation Paradigms on the Novel Object Recognition Task in a Rat Model of Alzheimer Disease

2019 ◽  
Vol 8 ◽  
pp. e1440
Author(s):  
Amir Hossein Zarifkar ◽  
Asadollah Zarifkar ◽  
Mohammad Nami ◽  
Ali Rafati ◽  
Hadi Aligholi ◽  
...  
Keyword(s):  
Electrical Stimulation ◽  
Cognitive Impairment ◽  
Object Recognition ◽  
Alzheimer Disease ◽  
Cognitive Capacity ◽  
Male Rats ◽  
Transcranial Electrical Stimulation ◽  
Novel Object Recognition ◽  
Novel Object ◽  
Exploration Time

Background: Treatment of Alzheimer as a disease that is associated with cognitive impairment has been associated with some restrictions. Recently, researchers have focused on non-pharmacological treatments, including non-invasive stimulation of the brain by transcranial electrical stimulation (tES). Four main paradigms of transcranial electrical current include transcranial direct current stimulation (tDCS), transcranial alternative current stimulation (tACS), transcranial random noise stimulation (tRNS), transcranial pulse current stimulation (tPCS). The tDCS is a possible new therapeutic option for patients with cognitive impairment, including Alzheimer disease. Materials and Methods: The study was done on Sprague-Dawley male rats weighing 250-270 g. to develop Alzheimer’s model, the cannula was implanted bilaterally into the hippocampus. Aβ 25-35 (5μg/ 2.5µl/day) was microinjected bilaterally for 4 days. Then, an electrical stimulation paradigm was applied to the animal for 6 days. Animal cognitive capacity was evaluated on day 11 and 12 by novel object recognition (NOR) test. Results: Our results showed that application of tDCS; tACS; tRNS and tPCS reversed beta-amyloid-induced impairment (P<0.05). The tRNS Group spent total exploration time around the objects compared to other groups (P<0.05). There was no significant difference between the four different paradigms in discrimination ratio and the percentage of total exploration time. Conclusion: The results of this study showed that the use of multiple sessions of different tES paradigms could improve Aβ-induced memory impairment in the NOR test. Therefore, based on evidence, it can be expected that in addition to using tDCS, other stimulatory paradigms may also be considered in the treatment of AD. [GMJ.2019;8:e1440]

Ameliorative Effects of Different Transcranial Electrical Stimulation Paradigms on the Novel Object Recognition Task in a Rat Model of Alzheimer Disease

2019 ◽  
Vol 8 ◽  
Author(s):  
Amir Hossein Zarifkar ◽  
Asadollah Zarifkar ◽  
Mohammad Nami ◽  
Ali Rafati ◽  
Hadi Aligholi ◽  
...  
Keyword(s):  
Electrical Stimulation ◽  
Cognitive Impairment ◽  
Object Recognition ◽  
Alzheimer Disease ◽  
Cognitive Capacity ◽  
Male Rats ◽  
Transcranial Electrical Stimulation ◽  
Novel Object Recognition ◽  
Novel Object ◽  
Exploration Time

Background: Treatment of Alzheimer as a disease that is associated with cognitive impairment has been associated with some restrictions. Recently, researchers have focused on non-pharmacological treatments, including non-invasive stimulation of the brain by transcranial electrical stimulation (tES). Four main paradigms of transcranial electrical current include transcranial direct current stimulation (tDCS), transcranial alternative current stimulation (tACS), transcranial random noise stimulation (tRNS), transcranial pulse current stimulation (tPCS). The tDCS is a possible new therapeutic option for patients with cognitive impairment, including Alzheimer disease. Materials and Methods: The study was done on Sprague-Dawley male rats weighing 250-270 g. to develop Alzheimer's model, the cannula was implanted bilaterally into the hippocampus. Aβ 25-35 (5μg/ 2.5µl/day) was microinjected bilaterally for 4 days. Then, an electrical stimulation paradigm was applied to the animal for 6 days. Animal cognitive capacity was evaluated on day 11 and 12 by novel object recognition (NOR) test. Results: Our results showed that application of tDCS; tACS; tRNS and tPCS reversed beta-amyloid-induced impairment (P<0.05). The tRNS Group spent total exploration time around the objects compared to other groups (P<0.05). There was no significant difference between the four different paradigms in discrimination ratio and the percentage of total exploration time. Conclusion: The results of this study showed that the use of multiple sessions of different tES paradigms could improve Aβ-induced memory impairment in the NOR test. Therefore, based on evidence, it can be expected that in addition to using tDCS, other stimulatory paradigms may also be considered in the treatment of AD. [GMJ. 2019;inpress:e1440]

Dopamine D4 receptor stimulation contributes to novel object recognition: Relevance to cognitive impairment in schizophrenia

2017 ◽  
Vol 31 (4) ◽  
pp. 442-452 ◽  
Author(s):  
Masanori Miyauchi ◽  
Nichole M Neugebauer ◽  
Herbert Y Meltzer
Keyword(s):  
Cognitive Impairment ◽  
Object Recognition ◽  
Effective Dose ◽  
Atypical Antipsychotic ◽  
Novel Object Recognition ◽  
The Novel ◽  
Receptor Stimulation ◽  
Atypical Antipsychotic Drug ◽  
Novel Object ◽  
D4 Receptor

Several atypical antipsychotic drugs (APDs) have high affinity for the dopamine (DA) D4 receptor, but the relevance to the efficacy for the treatment of cognitive impairment associated with schizophrenia (CIAS) is poorly understood. The aim of this study was to investigate the effects of D4 receptor stimulation or blockade on novel object recognition (NOR) in normal rats and on the sub-chronic phencyclidine (PCP)-induced novel object recognition deficit. The effect of the D4 agonist, PD168077, and the D4 antagonist, L-745,870, were studied alone, and in combination with clozapine and lurasidone. In normal rats, L-745,870 impaired novel object recognition, whereas PD168077 had no effect. PD168077 acutely reversed the sub-chronic phencyclidine-induced novel object recognition deficit. Co-administration of a sub-effective dose (SED) of PD168077 with a sub-effective dose of lurasidone also reversed this deficit, but a sub-effective dose of PD168077 with a sub-effective dose of clozapine, a more potent D4 antagonist than lurasidone, did not reverse the sub-chronic phencyclidine-induced novel object recognition deficit. At a dose that did not induce a novel object recognition deficit, L-745,870 blocked the ability of clozapine, but not lurasidone, to reverse the novel object recognition deficit. D4 receptor agonism has a beneficial effect on novel object recognition in sub-chronic PCP-treated rats and augments the cognitive enhancing efficacy of an atypical antipsychotic drug that lacks affinity for the D4 receptor, lurasidone.

Pregnenolone sulfate infused in lateral septum of male rats impairs novel object recognition memory

2010 ◽  
Vol 62 (2) ◽  
pp. 265-272 ◽  
Author(s):  
Federico Nanfaro ◽  
Ricardo Cabrera ◽  
Vanesa Bazzocchini ◽  
Myrian Laconi ◽  
Roberto Yunes
Keyword(s):  
Object Recognition ◽  
Recognition Memory ◽  
Lateral Septum ◽  
Male Rats ◽  
Novel Object Recognition ◽  
Pregnenolone Sulfate ◽  
Novel Object ◽  
Object Recognition Memory

scholarly journals Rosuvastatin Improves Cognitive Function of Chronic Hypertensive Rats by Attenuating White Matter Lesions and Beta-Amyloid Deposits

2020 ◽  
Vol 2020 ◽  
pp. 1-9
Author(s):  
Lu Zheng ◽  
Ying Cai ◽  
Baoshan Qiu ◽  
Linfang Lan ◽  
Jing Lin ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Object Recognition ◽  
Cognitive Function ◽  
White Matter ◽  
Water Maze ◽  
Novel Object Recognition ◽  
Hypertensive Rats ◽  
Object Recognition Test ◽  
Novel Object ◽  
Novel Object Recognition Test

Hypertensive white matter lesion (WML) is one of common causes of vascular cognitive impairment. In this study, we aimed to investigate the effect of rosuvastatin on cognitive impairment and its underlying mechanisms in chronic hypertensive rats. From the 8th week after establishment of stroke-prone renovascular hypertensive rats (RHRSPs), rosuvastatin (10 mg/kg) or saline as a control was administrated once daily for consecutive 12 weeks by gastric gavage. Cognitive function was assessed with the Morris water maze test and novel object recognition test. WML was observed by Luxol fast blue staining. Aβ deposits, Claudin-5, Occludin, and ZO-1 were determined by immunofluorescence. After rosuvastatin treatment, the escape latencies were decreased and the time of crossing the hidden platform was increased in the Morris water maze, compared with the vehicle-treated RHRSP group. In a novel object recognition test, the recognition index in the rosuvastatin-treated RHRSP group was significantly larger than that in the vehicle-treated RHRSP group. Rosuvastatin treatment presented with the effects of lower WML grades, higher expression of tight junction proteins Claudin-5, Occludin, and ZO-1 in the corpus callosum, and less Aβ deposits in the cortex and hippocampus. The data suggested that rosuvastatin improved the cognitive function of chronic hypertensive rats partly by attenuating WML and reducing Aβ burden.

Sign in / Sign up

Export Citation Format

Share Document